| Keyword Submission Number(s) | |
| 16p11.2 T81 | |
| 17-β-estradiol M166 | |
| 1H MRS 30.2, T122 | |
| 1H-MRS W45, W128 | |
| 25CN-NBOH W200 | |
| 31P magnetic resonance spectroscopy 54 | |
| 3D genome 25.3 | |
| 5-HT1A receptors M98 | |
| 7-dehydrocholesterol T117 | |
| 7T T69 | |
| ABCD study 55, W31 | |
| Abstinence T41, T55 | |
| Abuse Liability M175, T149 | |
| Abuse potential M139, T157, W150 | |
| Acamprosate W23 | |
| Accelerated aging T10, W130 | |
| Acetylcholine 14.2 | |
| Acetylcholine esterase inhibitors T150 | |
| acoustic startle response 14.4, M75, T91 | |
| Actigraphy W43 | |
| Activated microglia 43, 43.5 | |
| Activity-regulated cytoskeleton-associated protein W55 | |
| Acute effects T168, W174 | |
| Acute stress 28.1, 34.2, M43, W14 | |
| Acute traumatic stress M5 | |
| Adaptive behavior M16 | |
| Adaptive deep brain stimulation 9, 9.3 | |
| Addiction 7.4, 9, 32.2, 34, 34.2, 34.4, 41.3, 44, 47.2, 49.3, 49.5, M47, M147, M167, T124, T172, T175, T193 | |
| Addiction circuitry 34.5, M141, W190 | |
| Addiction phenotypes 39.1, T195, W161, W181 | |
| Adenosine signaling W185 | |
| Adenosine triphosphate (ATP) 54.3 | |
| ADHD 12, 12.2, M27, T13, W25, W37 | |
| Adjunctive therapy M86 | |
| ADNI W103 | |
| Adolescence 13, 23.3, 39.2, 39.3, M107, M183, T14, T76, T85, T114, W34 | |
| Adolescence—critical period 39, M119 | |
| Adolescent 12.4, 39.4, M177, T11 | |
| Adolescent alcohol M178 | |
| Adolescent alcohol exposure 41 | |
| Adolescent anxiety 39.4, T164 | |
| Adolescent brain cognitive development study T198 | |
| Adolescent depression 13.3, M35, M61, M65, T26 | |
| Adolescent development M26 | |
| Adolescent PTSD M12 | |
| Adolescent stress W80 | |
| Adolescents M25, M27 | |
| Adult hippocampal neurogenesis T29 | |
| adverse childhood experiences (ACE) 13.4 | |
| Adversity 34 | |
| Aerobic exercise 12.4, W169 | |
| Affect 44 | |
| Affective disorders T21 | |
| Affective neuroscience W11 | |
| African Americans T10 | |
| Ageing 20.2, 31, 31.2, T103, T114 | |
| Aggression 11, W182 | |
| Aggressive behavior 28 | |
| Aging 4, 31.3, T64, T186, W2, W3, W58 | |
| Air pollution T77 | |
| Alcohol 7.4, 41.2, M152, M167, M173, M186, T72, T161, T176, T179, T181, T188, T194, W146, W165, W172 | |
| Alcohol relapse treatment 7.2, 41, M176 | |
| Alcohol and substance use disorders 7.3, M160, M176, M191, M192, T42, T164, T172, T195, W181, W182 | |
| Alcohol consumption 7.2, 41.5, M178 | |
| Alcohol dependence M149 | |
| Alcohol drinking 41, M145, M165, T194, W168 | |
| Alcohol sensitivity W174 | |
| Alcohol use disorder 7, 7.5, 41.4, M149, M159, M163, M169, T43, T55, T183, T186, W147, W157, W165 | |
| Alcohol use disorder—treatment M173, T42, T46, T185, T190, W151, W180 | |
| Alcohol use disorder metabolism reward T177 | |
| Alcohol withdrawal T39, W41, W162 | |
| Alcoholic liver disease T185 | |
| Alcoholism T175, W156 | |
| Alcohol-seeking behavior 41 | |
| Allopregnanolone 48.5, T190 | |
| Alpha T34 | |
| Alpha oscillations W116 | |
| Alpha-7 nicotinic acetylcholine receptor M178 | |
| Alpha-adrenergic T186 | |
| Altitude 3, 3.2 | |
| Alzheimer’s disease 15, 15.4, T124, T64, W4, W100, W103, W107 | |
| AMPA receptors T188 | |
| Amphetamine M101, M147, M198, T174, W166 | |
| Amygdala 14.5, 38.2, 45.3, M149, T9, T73, T118, W21, W26, W85, W187 | |
| Amygdala-hippocampal differences M57 | |
| Analgesics M82 | |
| Anhedonia 23.5, M56, M77, T158, W97 | |
| Animal model 3.2, 4, 46.1, M148, T38 | |
| Animal models 40, M85, M195, T105, W29, W105, W177 | |
| Animal research T179, W15 | |
| Anorexia nervosa M43, T15, T87, T89 | |
| Antagonist ligands T49 | |
| Anterior cingulate cortex W196 | |
| Anterior cingulate cortex (ACC) M131, M163, T67, W26, W68, W193 | |
| Anterior insula T16 | |
| Antidepressant 5.5, 47.2, M68, M83, M85, T29, W65, W99 | |
| Antidepressant response W67 | |
| Antidepressant trials W76 | |
| Antidepressants M50, M87, W74, W97 | |
| Antipsychotic T110, T148 | |
| Antipsychotic drug 30.3 | |
| Antipsychotic drugs 30, 30.4 | |
| Antipsychotic induced weight gain M37 | |
| Antipsychotic medication 18 | |
| Antipsychotic response M128, W127 | |
| Antipsychotic treatment W90 | |
| Antipsychotic-induced metabolic dysfunction 30.3 | |
| Antipsychotic-induced weight gain T37 | |
| Antipsychotic-naïve first-episode schizophrenia 30.2, 42.5 | |
| Antipsychotics M112, M114, W128 | |
| Anxiety 3.3, 13.2, 23.3, 28.3, 39, M4, M169, T8, T11, T27, T44, T70, T73, T84, T105, T109, T113, W22, W41, W59, W195 | |
| Anxiety & PTSD T2, T12, W11, W17 | |
| Anxiety circuitry 14.3, M24, T74 | |
| Anxiety disorders T6 | |
| Anxiety model T28 | |
| Apoer2 M87 | |
| Apoptosis W54 | |
| Arc M6 | |
| Arousal 14, 14.2 | |
| ASD 26.3, M28, M29, T81 | |
| ASD core symptoms T75 | |
| Assessment W35 | |
| Associative learning T9, T52, T118 | |
| Astrocyte 36, 36.5, T51, T64, W152 | |
| Astrocyte-neuron interaction T166, W139 | |
| Astrocytes M146, T163 | |
| Astroglia T90 | |
| Astrogliosis 15.2 | |
| Attention M40, M198, M201, T57, T156, W4, W53, W152, W195, W196 | |
| Attention deficit hyperactivity disorder W51 | |
| Atypical antipsychotics M54, T111, W96 | |
| Auditory cortex 6.4, T33 | |
| Auditory fear conditioning T9, W18, W30 | |
| Auditory mismatch negativity T106 | |
| Auditory steady-state response M134 | |
| Augmentation M83 | |
| Autism 26.2, 26.4, M21, M22, M96, T75, W32, W39 | |
| Autism behavior inventory T75 | |
| Autism spectrum disorder 20.5, 42.3, M23, M31, T11, T78, T197, W26, W101 | |
| Autism spectrum disorder and related syndromes M30, T86 | |
| Autoantibody T146 | |
| Autobiographical memory T200, W85 | |
| Autonomic M113 | |
| Autonomic nervous system 29.4, 51.3, M14, W88 | |
| aV1ation W101 | |
| Aversive learning M190 | |
| Avoidance M2, M5 | |
| Axon guidance molecule genes 39.1 | |
| Axons W108 | |
| Balloon effort task M126 | |
| Balovaptan W101 | |
| Bariatric surgery W47 | |
| Basal forebrain M155 | |
| Basal ganglia 9.4, M101, W190 | |
| Basolateral amygdala 48.5, M20, T85, W28 | |
| Bayesian inference M199 | |
| BDNF M34, M90, T127, W61, W169 | |
| BDNF Val66Met W79 | |
| Behavior M15, T91, W98 | |
| Behavioral flexibility M59, W189 | |
| Behavioral genetics W162 | |
| Behavioral pharmacology M152, T191, W15, W161 | |
| Behavioral phenotyping T105 | |
| Behavioral tasks 40, M62 | |
| Behavioural neuroscience W15 | |
| Belief updating 6.2 | |
| BI 1358894 T94 | |
| BI 425809 T134, T135 | |
| Bifactor M4 | |
| Big data T43 | |
| Binge drinking T188, W34, W149 | |
| Binge eating 9.2 | |
| Binge-drinking W182 | |
| Bioenergetics 3.2, 54.5 | |
| Bioenergetics and insulin resistance 30 | |
| Bioinformatics W56 | |
| Biological pathway analysis W102 | |
| Biomarker 51, M92, T117, W34, W100 | |
| Biomarkers 23.4, 51.1, W17 | |
| Biomarkers for risk assessment 21, W126 | |
| Bipolar depression W90 | |
| Bipolar disorder 2.2, 12, 12.3, 12.1, 12.2, 12.4, 25.2, 31, 31.1, 31.2, 31.3, 38.4, 38.5, 45.1, 54.3, 54.4, M54, M58, M60, M64, M67, M71, M124, M200, T92, T97, T103, T110, T141, W54, W58, W72, W87, W90, W125 | |
| Bipolar I & II disorder T110, W132 | |
| Bipolar I depression T110, W96 | |
| Bipolar I disorder W94 | |
| Blood pressure W88 | |
| Blood-brain-barrier 36.3 | |
| BNST M116, M192, T55 | |
| Bodily self disturbance 47.4 | |
| Body dysmorphic disorder M103 | |
| Body mass index M74 | |
| Borderline personality disorder M105, T131 | |
| Brain 54.5, M16 | |
| Brain age 31, T68 | |
| Brain aging W5 | |
| Brain based markers for depression M91 | |
| Brain circuitry M31 | |
| Brain connectivity W155 | |
| Brain development 2.3, 24.4, 38.2, M30, M31, M33, W133 | |
| Brain imaging 12, 42, M19, T76, T87, W47, W67 | |
| Brain initiative 19, 19.2 | |
| Brain networks 24.1, T59 | |
| Brain organoids 52.4 | |
| Brain regulation of metabolism 30.4 | |
| Brain reward center M148 | |
| Brain stress T60 | |
| Brain structural connectivity M66, W33 | |
| Brain structure M115 | |
| Brain ventricular volume M72 | |
| Brain-derived neurotrophic factor M20 | |
| Brexanolone injection M80, W92 | |
| Bumetanide W2 | |
| Butyrate W112 | |
| Caffeine M27 | |
| Calcium imaging 52.3, M102, M146, T19, T119, W19, W139 | |
| Cannabidiol M39, M175 | |
| Cannabinoids 16, M157, M183, T126 | |
| Cannabis M158, M174, M175, T158, T182, W135 | |
| Cannabis use T168 | |
| Cannabis use disorder M150, M158 | |
| Cardiac autonomic tone 3.4 | |
| Cardiometabolic risk T152 | |
| Cardiovascular disorders 3, 12.4 | |
| Cardiovascular physiology W130 | |
| Cariprazine M164, T113 | |
| Catatonia 45.2, 45.3 | |
| Category learning T22 | |
| Causal modeling T43 | |
| CB2 W38 | |
| CBT T128 | |
| Cdk5 W7 | |
| Cell adhesion molecules T124 | |
| Centanafadine W51 | |
| Central amygdala M5, M141 | |
| Central autonomic network 3.4 | |
| Central nucleus of the amygdala M176 | |
| Cerebellum M193 | |
| Cerebral blood flow W32 | |
| c-Fos M6, M44, W22 | |
| Chemogenetics 32.2, T194 | |
| Chemotherapy-induced peripheral neuropathy T125 | |
| Child abuse and neglect M12 | |
| Child and adolescent psychiatry 2.3 | |
| Child psychopharmacology T198, W35 | |
| Childhood trauma 38.2, 51, 51.2, M55, T183 | |
| Children 12.3, T12, T79 | |
| Children and adolescents 5.3, 38, W35 | |
| Choline T122 | |
| Cholinergic system W3 | |
| Choroid plexus 36, 36.2, T15 | |
| CHRNA5 W53 | |
| Chronic pain 27, 27.3, M99, T122, W40 | |
| Chronic pain treatment W40 | |
| Chronic social defeat M77, T18, T115 | |
| Chronic stress M94, T17, T85, W66, W99, W115 | |
| Chronic unpredictable mild stress W7 | |
| Chrono-pharmacology W94 | |
| Circadian M106 | |
| Circadian rhythms 37.4, 49, 49.5, T159, W54, W94, W125, W163 | |
| Circuit T30 | |
| Circuit optogenetics 14, 32, 32.2, W18, W190 | |
| Circuit-function M100 | |
| Circuitry-based approach T17 | |
| Circulating mitochondrial DNA 51.3, 54.5, T82 | |
| Citalopram M11 | |
| Classification 42.3, W50 | |
| Claustrum T62 | |
| Clinical development M110 | |
| Clinical heterogeneity 2.4 | |
| Clinical high risk for psychosis 8, W117 | |
| Clinical high risk state for psychosis 30.2, W120 | |
| Clinical high-risk of psychosis 21, M132 | |
| Clinical interventions M36 | |
| Clinical neurobiology T172, T195 | |
| Clinical psychiatry 17 | |
| Clinical subtypes T89 | |
| Clinical transition 53 | |
| Clinical trial 28.3, M58, M152, W10, W23, W60, W113 | |
| Clinical trial design T46 | |
| Closed-loop control 19 | |
| Closed-loop deep brain stimulation 9.2, 19.5, 46.4 | |
| Clozapine M114 | |
| Cluster analysis M172 | |
| Cluster headache 47.5 | |
| CNS depressant drugs M127 | |
| CNV T81 | |
| Cocaine 36.5, 49.4, M16, M164, M185, T48, T165, T173, T174, W176, W187 | |
| Cocaine addiction M151, M154, M156, T180, W142, W145 | |
| Cocaine seeking 10.4, W143, W167, W183 | |
| Cocaine self-administration M146, T149, T163, T184, W175 | |
| Cocaine self-administration and reinstatement 52.2, M157, W167, W169 | |
| Cocaine sex differences T163 | |
| Cocaine use disorder 25.2 | |
| Cognition 24, 44, M40, M113, M182, T35, T65, T122, T157, W116, W123, W154 | |
| Cognitive T20 | |
| Cognitive control 9.3, W196 | |
| Cognitive decline M94 | |
| Cognitive deficits 21 | |
| Cognitive development 36.4 | |
| Cognitive flexibility 9, M155, M195, T80, W200 | |
| Cognitive functioning M114, W113 | |
| Cognitive impairment M58, T134 | |
| Cognitive impairments T138 | |
| Cognitive impairment W174 | |
| Cognitive neuroscience 6, T80 | |
| Cognitive remediation M134 | |
| Cognitive training M157, T6 | |
| Cognitive/emotional task performance 13.3 | |
| Collaborative cross and diversity outbred mice W163 | |
| Combat PTSD M7, M9, T72 | |
| Common deletion 54.2 | |
| Common SNPs T23 | |
| Common variant T36 | |
| Communication barriers M22 | |
| Comorbidity 17, 31, 31.2 | |
| Complement factor C4 43, 43.4, 43.5 | |
| Complex I activity 54.2 | |
| Compulsion 41.2, M104 | |
| Compulsive behavior T188 | |
| Compulsive eating W24 | |
| Compulsive models of drug use M145 | |
| Computational modeling T21, T22 | |
| Computational modelling 6.5 | |
| Computational models of decision-making 41.3 | |
| Computational neuroscience 6, W69 | |
| Computational psychiatry M10, W70 | |
| Computational reinforcement learning model 39.3 | |
| Conditioned fear memory M169 | |
| Conditioned place preference M147, W145 | |
| Connectivity 43.2, M122 | |
| Consciousness T58 | |
| Context M177 | |
| Contextual cue T3 | |
| Contextual fear W30 | |
| Continuous performance task W115 | |
| Coping 31.1, 34.4 | |
| Copy number variants 2 | |
| Cortical circuit function 42.3, 45.2, W138 | |
| Cortical development 24.1 | |
| Cortical excitability M35, M93 | |
| Cortical excitation-inihibition balance W93 | |
| Cortical GABA T155 | |
| Cortical inhibition M93, T153 | |
| Cortical plasticity T34 | |
| Cortical thickness M159, T102, T133 | |
| Corticolimbic W157 | |
| Corticospinal tract W170 | |
| Corticosterone W79 | |
| Corticostriatal networks 9 | |
| Cortico-striatal plasticity 48.4 | |
| Corticotropin-releasing factor (CRF) M138, T17, W187 | |
| Cortisol 27, T7, W165 | |
| Cortisol response to stress T96, W156 | |
| Court-involved youth M36 | |
| COVID-19 17, 33, 50, M17, M181, M197, T159, W12, W43 | |
| Craving 36.2, M173, T44 | |
| Creatine M124 | |
| Creatine kinase 54.3 | |
| Creativity W37 | |
| CRF W149 | |
| CRH 34.3, M162, W28 | |
| CRISPR screens 20.4 | |
| CRISPR/Cas9 20, 20.5, W148 | |
| CRISPR/dCas9 W7 | |
| Cross species 34 | |
| Cross-species translation 22 | |
| CRP T72 | |
| Cue reactivity M156, M164, T173, T184 | |
| Cue reinstatement T187 | |
| Cue-exposure T2 | |
| Curriculum W44 | |
| Cyclooxygenase 15.5 | |
| CYP2C19 T100 | |
| CYP2D6 T100 | |
| Cytochrome P450s T100 | |
| Cytokines W129 | |
| D1 dopamine receptors W140, W159, W166 | |
| D2 dopamine receptor 10.4, T91, W140 | |
| D3 receptor T191 | |
| D3 receptor partial agonist M164 | |
| Dabigatran T94 | |
| Daridorexant M137 | |
| Data fusion T1 | |
| Daytime functioning M137 | |
| DBS 9.4 | |
| Decision making M16, W192, W193 | |
| Deep brain stimulation 9.1, 46, 46.1, 46.2, 46.3, W49, W83 | |
| Deep sequencing 2 | |
| Default mode network (DMN) 13.4, T62, T200 | |
| Defensive and motivated behaviors 27.2, W21 | |
| Delay discounting T44 | |
| Delta 6.4 | |
| Delta opioid receptors 32.5 | |
| Delusions M129 | |
| Dementia 4, M129, T150 | |
| Dendrites M107, W108 | |
| Dendritic morphogenesis M193 | |
| Dentate gyrus M59 | |
| Dependence W150 | |
| Depression 2.1, 3.3, 15.3, 19.5, 23.5, 32.3, 36.3, 37, 37.2, 38.4, 38.5, 45.1, 46, 48, 49.3, M17, M55, M62, M63, M68, M69, M71, M72, M78, M79, M83, M131, M200, T20, T29, T92, T98, T101, T102, T107, T113, W27, W50, W63, W64, W66, W75, W83, W86, W87, W88, W89, W97, W99, W199 | |
| Depression and anxiety 23, M161, T56, W72 | |
| Depression inflammation M92 | |
| Depressive symptoms T148 | |
| Depressive-like behavior T105 | |
| Desmosterol T117 | |
| Devaluation M135 | |
| Development M32, W30 | |
| Developmental T76 | |
| Developmental neuropsychiatric disorders T81 | |
| Developmental psychopathology 13, 13.1 | |
| Developmental trajectory 51.3, T82, W159 | |
| Diabetes 23.2 | |
| Diabetic peripheral neuropathy T125 | |
| Diagnosis W87, W90 | |
| Diagnostic prediction 26.4 | |
| Dietary supplement W113 | |
| Diffusion tensor imaging (DTI) 12.2 | |
| Diffusion tractography 46.2 | |
| Diffusion weighted imaging 45, T144, W33 | |
| Digital phenotyping W36 | |
| Dimensional child psychopathology W31 | |
| Discrimination 52.1, W27 | |
| Disorders of glutamate M124 | |
| Distress intolerance M160 | |
| Diverse animal models W69 | |
| Diversity 1, 35 | |
| DLPFC W109 | |
| DNA M120 | |
| DNA methylation M18, T33, W58 | |
| DNA sequencing 2.2 | |
| Dopamine 5.2, 6.3, 19.3, 27, 27.2, 30.3, 34.5, M1, M16, M47, M51, M58, M101, M127, M155, M180, M184, M186, M198, T52, T63, T113, T147, T158, T189, W2, W45, W173, W176, W189 | |
| Dopamine (D2, D3) receptors 30.3, M184, W166, W171 | |
| Dopamine and serotonin 45.1 | |
| Dopamine D3 receptors W178 | |
| Dopamine D4 receptor T49 | |
| Dopamine receptor type 2-expressing striatal medium spiny neuron M201 | |
| Dopamine release 52.2 | |
| Dopamine3 receptors 52, 52.2 | |
| Dopamine-deficient mice M98 | |
| Dorsal Hippocampus T65 | |
| Dorsal raphe M180 | |
| Dorsal striatum T63, W41, W45, W139 | |
| Dorsolateral prefrontal cortex T133 | |
| Dose response W146 | |
| DREADD 49.3 | |
| DREADDs W141, W149 | |
| Drosophila T181 | |
| Drug abuse 39 | |
| Drug addiction 49, M179, T48, T162, W176 | |
| Drug cues M154, W186 | |
| Drug development 21 | |
| Drug discovery—new approaches M31 | |
| Drug discovery/development T124 | |
| Drug discrimination W51 | |
| Drug relapse M142, T50, T196 | |
| Drug self-administration M142 | |
| D-serine M118 | |
| DTI M46, M112, T1 | |
| Dual orexin receptor antagonist M137, W134, W150 | |
| Duration of untreated psychosis T144 | |
| Dynamic connectivity 42.2, M103 | |
| Dynamic functional connectivity 42.3 | |
| Dynamic neural modeling 19.5 | |
| Dynamical systems W136 | |
| Dynamics M122 | |
| Dysregulation T141 | |
| Early adolescence 24.4 | |
| Early childhood 12.1 | |
| Early life adversity M162, T123, W28 | |
| Early life stress 23.4, 34.3, M25, M48, M52, M71, M184, M194, T77, T178, W29, W38, W142, W195 | |
| Early parental loss T123 | |
| Early psychosis M109, M123 | |
| Early rearing T83 | |
| Eating disorders T88 | |
| Ecological momentary assessment T159, W36, W43, W117, W132 | |
| Education and training 33, W44 | |
| EEG 26, 47.4, T25, T34, T58 | |
| EEG biomarkers 6.5, 13.1, 26.2, M7, M196, M198, W4, W93, W116 | |
| EEG/ERP electrophysiology M195, T106, W195 | |
| EEG-fMRI W136 | |
| Efficacy and safety M110 | |
| Effort based decision making task T19, W193 | |
| Electrical field modeling W10 | |
| Electrochemistry M171 | |
| Electroconvulsive therapy M78, T92, T104 | |
| Electroencephalography T135, W100 | |
| Electron microscopy T147 | |
| Electronic cigarette (e-cigarette) M181 | |
| Electrophysiology 9.1, 49.4, W18, W135 | |
| Emotion circuitry T88 | |
| Emotion modulation M105, W65 | |
| Emotion perception T57 | |
| Emotion processing W65 | |
| Emotion regulation M60, W191 | |
| Emotional dysregulation 31.1 | |
| Emotional memory 13.3 | |
| Emotional regulation 31, 38, M197 | |
| Emotional stress T98 | |
| Empathy W158 | |
| Endocannabinoid system M19, M180, T132, W172 | |
| Endocannabinoids M188 | |
| Endogenous opioids 10.1, 10.3, T54 | |
| Endogenous retrovirus 25.3 | |
| Engram 52, M6, M42 | |
| Enkephalin 10.3, 10.4 | |
| Entropy T86 | |
| Environmental enrichment W56 | |
| Epidemiology 2.4, M68 | |
| Epigenetic 32.3, 52, 52.1, W142, W180 | |
| Epigenetic modification M149 | |
| Epigenetic regulation 32 | |
| Epigenetics 25.4, M15, M47, M52, M76, M121, T33, T162, T164, T165, T176 | |
| Epigenome wide association studies T176 | |
| Epilepsy M40, W105 | |
| ERK M90 | |
| ER-β M166 | |
| Escitalopram T24, W93 | |
| Esketamine M81 | |
| Esketamine nasal spray T93, T95, W62 | |
| Estradiol W81 | |
| Estrogen receptor M51 | |
| Estrogen synthesis T15 | |
| Estrous T187 | |
| Ethanol W139, W179 | |
| Ethics 16 | |
| Ethinyl estradiol M166 | |
| Event-related potentials M158, T57, T80, W119 | |
| EWAS W103 | |
| Excitation-inhibition balance T132, W122 | |
| Excitatory and inhibitory imbalance hypothesis M93 | |
| Excitatory synapses 52.4 | |
| Executive function 3.3, T195 | |
| Exome sequencing 2.2 | |
| Experimental design T20 | |
| Experimental medicine 41.5, W100 | |
| Explore-exploit dilemma W192 | |
| Exposure therapy T128 | |
| Exposure-response M129 | |
| Externalizing behavior T79 | |
| Externalizing disorders 13.1 | |
| Extinction T162 | |
| Extinction learning W183 | |
| Extinction recall 38.2 | |
| Extracellular vesicles 51, 51.3 | |
| Extrapyramidal symptoms M125 | |
| Eye tracking 26, 26.3, T20 | |
| Face emotion processing T22 | |
| Facial emotional processing T78 | |
| Familial risk 38.4, 38.5, M61 | |
| Family study 12.1 | |
| Fast scan cyclic voltammetry T189 | |
| Fatty acids T89 | |
| Fear M18, W19 | |
| Fear conditioning 36.4, M6, W20, W21 | |
| Fear conditioning and extinction T2, T3, T4, T12, W16 | |
| Fear extinction 39.2, M86, T14 | |
| Fear generalization 52.1, T2 | |
| Fear learning M24 | |
| Fear-potentiated startle W17 | |
| Fecal microbiome transportation M77 | |
| Feeding behavior M41, M42 | |
| Females 23.2 | |
| Fentanyl 10.2, 49.5, M179, T41, T192, W178 | |
| Fetal exposures of alcohol and other drugs M11 | |
| FFA M117 | |
| Fiber photometry 5.2, M40, M186, T52, T127 | |
| Fibroblasts W163 | |
| First episode psychosis T144, W127 | |
| FKBP5 M71, W78 | |
| Flanker task M196 | |
| Fluoxetine M90, T18 | |
| Functional MRI (fMRI) 5.3, 12, 13.2, 27.3, 38.3, 38.5, 41.4, 42.3, 45, 45.3, 47.4, M4, M19, M23, M60, M122, M131, M154, M164, T3, T6, T21, T56, T60, T61, T70, T76, T87, T200, W25, W46, W67, W114, W117, W158, W186, W192, W195, W198 | |
| fMRI effective Connectivity M103, T5 | |
| fMRI faces paradigm M103 | |
| fMRI functional connectivity T62, T78, W173 | |
| Focused ultrasound 19.4 | |
| Food cues W46 | |
| Forced swim test W29 | |
| Four-core genotype mouse W179 | |
| Fractional amplitude of low frequency fluctuations M61 | |
| Fragile X syndrome T80, W23 | |
| FreeSurfer M72, T131 | |
| Frontolimbic network M14 | |
| Frontoparietal network W4 | |
| Frontostriatal circuitry W33 | |
| Fronto-striatal networks M61 | |
| Frustrative non-reward 5.2, 5.3 | |
| Functional capacity M114 | |
| Functional connectivity M96, W47 | |
| Functional magnetic resonance spectroscopy T69 | |
| Functional near-infrared spectroscopy T182 | |
| Functional neuroimaging M56, W164 | |
| Functional variants T23 | |
| Functioning W121 | |
| G9a W180 | |
| GABA 45, M128, T153, T190, W2, W5 | |
| GABA neuron M133 | |
| GABA-A receptors M28, M75, T199 | |
| GABAergic interneurons 48, 48.3, T63, W18, W98 | |
| GAD M17 | |
| Galanin W144 | |
| Gamma 6.4, 24.2 | |
| Gamma oscillation 24, M188, W196 | |
| GAT-3 T166 | |
| Gender differences M74 | |
| Gene co-expression networks 37 | |
| Gene expression 32, 32.3, 52.1, M45, M148, M200, T16, T60 | |
| Gene-by-sex interaction 37.5 | |
| Gene-prioritization 20.3 | |
| Generalized anxiety disorder T73 | |
| Genetic association 25 | |
| Genetic association study 2 | |
| Genetic human model T13 | |
| Genetic risk factor W72 | |
| Genetic variability M19 | |
| Genetics 2.2, 37.5 | |
| Genetics of depression T23 | |
| Genome-wide association studies T140 | |
| Genomics 2.4, M121, W123, W124 | |
| Genotypes T100 | |
| Geriatric M78 | |
| Ghrelin T179 | |
| Glia 3.1 | |
| Globus pallidus 9.4, T131, W152 | |
| GLT-1 T163 | |
| Glucocorticoid receptor W78 | |
| Glucocorticoids W80 | |
| GluN2B M89 | |
| Glutamate 15.3, 43.2, M128, M185, M191, T145, T147, T175, T176, W5, W45 | |
| Glutamate GABA M145 | |
| Glutamate receptor function M94 | |
| Glutamate transporter (EAAT3) M101 | |
| Glycine transporter 1 inhibitor T135 | |
| Glyoxalase 1 W162 | |
| Goal-directed behaviors M135, T63, W193 | |
| Gonadal Hormones M48, W179 | |
| GPCRs 32.2 | |
| GPER1 T193 | |
| Graph theory M66, T88 | |
| Graph-based analysis W106 | |
| Grey matter morphometry M159 | |
| Guanfacine W22 | |
| Gut microbiome 29.2, 29.3, W130, W167 | |
| Gut microbiota W168 | |
| Gut-brain axis 7.3 | |
| GWAS 2.1, 20.2, 20.3, T174, W31, W102, W123 | |
| Habenula 28, 36.2 | |
| Habit W152 | |
| Habit formation 48.4 | |
| Hallucinations 6, 6.3, M129, M130 | |
| Hallucinogen W200 | |
| Handwriting M125 | |
| Harm avoidance 39.4 | |
| HCN M50 | |
| HDAC5 T162 | |
| Headache 32.5, 47.5 | |
| HEAL initiative W1 | |
| Health disparities 51.1, 51.4, T82, T183 | |
| Health promotion W12 | |
| Healthy controls M46 | |
| Heart rate variability 29.4, M14 | |
| Heritability M67, M70, M121 | |
| Heroin T40, W188 | |
| Heroin self-administration M184 | |
| Herpesvirus M97 | |
| Heterochromatin 25.3 | |
| Hierarchical perceptual inference W122 | |
| High fat diet M45 | |
| High potency THC M174 | |
| Hippocampal function W131 | |
| Hippocampal shape W133 | |
| Hippocampal subfields T77 | |
| Hippocampus 38.2, 38.3, M81, M84, M90, M117, T3, T154, W5, W19, W78, W79, W133, W137 | |
| Histone acetylation M149 | |
| Homeostatic plasticity M53 | |
| Homeostatic synaptic transmission W145 | |
| Hopelessness M60, W84 | |
| Horizontal pleiotropy 54.2 | |
| Housing M177 | |
| HPA axis T7, W78, W80 | |
| Human genetics M97 | |
| Human laboratory study T179 | |
| Human neuroimaging 13, T96, T101, T177, T180, T198, W70, W75, W76, W133, W191, W193 | |
| Human post-mortem brain 49.5, 54, M120 | |
| Human postmortem brain tissue M106 | |
| Humans T108 | |
| Hybrid PET/MR W166 | |
| Hydroxynorketamine T112 | |
| Hyperarousal 14.3, M13 | |
| Hyperlocomotion M127 | |
| Hypocretin 28 | |
| Hypothalamic-pituitary-adrenal axis W197 | |
| Hypothalamus T17 | |
| Ibudilast T42 | |
| Illness trajectory M199, T154 | |
| Immobility 32.4 | |
| Immune biomarkers 51.4, M165, T146 | |
| Immune function 3.4 | |
| Immune responses 3, 29.4, 51.4 | |
| Implicit bias 35 | |
| Implicit priming W46 | |
| Impulse control 9.2, M47 | |
| Impulsivity 9, 11, M46, M173, T8, T83, T169, T178, W52, W154, W186 | |
| In vivo calcium imaging 46.1, M104, T53, T54, W183 | |
| In vivo microscopy M102 | |
| Incentive motivation 10.1, T54, W189 | |
| Incentive salience M187, W184, W186 | |
| Incubation of drug craving 36.5, M142, M156 | |
| Individual differences M187, W70 | |
| Individual variation M172 | |
| Induced pluripotent stem cells (iPSCs) 20, 52.4 | |
| Infancy 13, 13.1, 26, 26.2, 26.3 | |
| Infant 26.4, W27 | |
| Inference 6 | |
| Inflammasome M2, W38 | |
| Inflammation 15, 15.3, 15.5, 23, 23.2, 23.3, 23.4, 23.5, 30, 30.2, 36.3, M38, T64, T72, T103, W9, W57, W129, W130 | |
| Inflammatory cytokines W81 | |
| Inflammatory markers T102 | |
| Information encoding M190 | |
| Inhibitory control T27 | |
| Inhibitory interneurons T126 | |
| Insomnia 20.3, 28.1, M137, M139, T97, T99, T116, T157, W92 | |
| Instrumental learning 39.3 | |
| Insula M115, M163, W117 | |
| Insular cortex T130 | |
| Insulin 30.3, W45 | |
| Insulin resistance 30.4, M74 | |
| Intergenerational depression M59 | |
| Interleukin-8 T24 | |
| Internal capsule 46.1 | |
| Internalizing behavior 13.1, T79 | |
| Internalizing disorders T8 | |
| Internet of things W48 | |
| Internet survey W160 | |
| Interneuron 24.2, 48.2 | |
| Interoception T73 | |
| Interpretation bias T22 | |
| Intracortical myelin W110, W118 | |
| Intracranial self-stimulation T47 | |
| Intravenous drug self-administration T48, T187, W178 | |
| Intrinsic excitability W184 | |
| Intrinsic functional connectivity W67 | |
| Intrinsic neural timescale W122 | |
| Ion channels M49, T52 | |
| iPSC W54 | |
| Irritability 5.3, 5.5, M4, T27, W199 | |
| Irritability/Aggression 5, 5.2, 5.4, 28.2, W50 | |
| IV—ketamine W88, W95 | |
| Juvenile critical period 24.3 | |
| Juvenile social isolation M1 | |
| Kappa agonist W180 | |
| Kappa opioid receptor antagonist T47 | |
| Kappa opioid receptors T171, T189, W157 | |
| Ketamine 16, 41.5, 47.3, M55, M57, M82, M86, M87, M130, T18, T112, T114, T115, W19 | |
| Ketogenic diet W151 | |
| Ketorolac M82 | |
| Kinases T39 | |
| Kynurenic acid T160 | |
| Kynurenine pathway M64, T160 | |
| Kynurenines 15.3 | |
| L1 retrotransposons 25.2 | |
| Language delay T121 | |
| Large scale networks 45 | |
| Late life depression W95 | |
| Late-life depression W71 | |
| Latent factor analysis T27, T61 | |
| Lateral habenula 28.2, M192 | |
| Lateral hypothalamus M5 | |
| Lateral inhibition T138 | |
| Lateral orbitofrontal cortex M104, M135 | |
| Lateral septum M20, M43 | |
| Learning M16 | |
| Learning and memory M42, M95, W5, W194 | |
| Learning theory T2 | |
| Lemborexant M139, T157 | |
| Leptin M74 | |
| Lesion W75 | |
| Leukocyte telomere length M38 | |
| Lifetime stress 29, T82 | |
| Limbic brain circuitry 37 | |
| Liquid chromatography/mass spectrometry 10.3, M171 | |
| Lithium M38, W54 | |
| Lithium response W94 | |
| Liver brain axis T176 | |
| Local field potentials W49 | |
| Locus coeruleus 49.3, T173 | |
| Long access self-administration T47 | |
| Long noncoding RNA 37.2 | |
| Long-acting injectable M125 | |
| Longitudinal W34 | |
| Longitudinal analysis M9, M117 | |
| Longitudinal imaging 38.3 | |
| Longitudinal MRI M81 | |
| Longitudinal studies 38 | |
| Longitudinal study 14.4, M199 | |
| Long-term depression W190 | |
| Long-term potentiation 32.4, T34 | |
| Loss W56 | |
| LSD 47.3, W49 | |
| LSD microdosing T108, W61 | |
| M1 and M4 muscarinic receptors M110 | |
| Machine learning M100, M121, T30, T59, T181, W49, W71, W155 | |
| Machine learning classification 42.5, M67 | |
| Magnesium W2 | |
| Magnetic resonance imaging 47, W137 | |
| Magnetic resonance spectroscopy M21, T67, T143, T145 | |
| Magnetic seizure therapy T25, T92 | |
| Major depression 37.5, 46.4, M54, W82 | |
| Major depressive disorder (MDD) 3.4, 5.5, M56, M57, M74, M92, M93, T23, T24, T25, T92, T93, T94, T95, T104, T117, W57, W59, W60, W67, W68, W70, W74, W199 | |
| Major depressive episode 15, 15.2 | |
| Mania 38.5, W50 | |
| Marijuana M158 | |
| Maternal behavior M15, W158 | |
| Maternal brain W158 | |
| Maternal depression 29.3, T167 | |
| Maternal immune activation 25.4 | |
| MATRICS consensus cognition battery (MCCB) T137 | |
| Matrix metalloproteinase-9 (MMP-9) M144, W14, W137 | |
| MCH neurons 49.4 | |
| MDD 2 | |
| MDMA W6 | |
| MDPV self-administration W175 | |
| MeCP2 W102 | |
| Medial orbitofrontal cortex T53 | |
| Medial prefrontal cortex 14.2, 24, 24.1, 24.3, 48.3, M42, T40, T65, T85, T156, W140 | |
| Medial septum M155 | |
| Medication adherence 18 | |
| Medication assisted treatment 11 | |
| Medication development 7.3 | |
| Medio-dorsal thalamus T53 | |
| Medium spiny neuron M49, M146, M150, M190, T41, W183 | |
| Memantine W100 | |
| Memory 36.4, W104 | |
| Memory and learning M143, T66 | |
| Memory encoding and retrieval W18 | |
| Memory reconsolidation 41.5, W187 | |
| Mendelian randomization 54.2 | |
| Menopause 3.3 | |
| Mental disorders W42 | |
| Mesocorticolimbic system T87 | |
| Mesolimbic reward circuitry 34.5, T51, W194 | |
| Meta-analysis 42.4, M64, T37, T143, T197, W86 | |
| Metabolic biomarker T177 | |
| Metabolic defect W129 | |
| Metabolism 23, 23.4, 23.5, T159, W167 | |
| Metabolomics 7.4, 29.3, M168, W168 | |
| Metabotropic glutamate receptor 5 (mglu5) T175 | |
| Methamphetamine M161 | |
| Methods 1 | |
| mGlu receptors 48.3 | |
| mGlu5 M191 | |
| mGlu5-NAM M182 | |
| mGluR5 receptors T127, W40 | |
| Mice 49.2 | |
| Microaggression 35 | |
| Microbiome 29, 51.4, M168 | |
| Microbiota-gut-brain axis M77 | |
| Microglia 29.2, M30, M33, M34, T64, T120 | |
| Microglia engulfment 43.4, W159 | |
| Microglia priming M76 | |
| Microglial activation 15.2 | |
| Microresistance 35 | |
| MicroRNA 39.1, T131, T141 | |
| Mifepristone 7.5 | |
| Migraine 47.5 | |
| Mild traumatic brain injury M7 | |
| Mindfulness M25 | |
| Mineralocorticoid receptor M167, W78 | |
| Miniscope 52, T119 | |
| Mismatch negativity 6.5 | |
| Mitochondria 23.3, 54, 54.2, 54.5, M33, M45, T112, W57 | |
| Mitochondrial DNA 54, W126 | |
| Mitochondrial dynamics W57 | |
| Mitophagy W57 | |
| Mobile DNA 25 | |
| Molecular genetics 2.1, M37, T124 | |
| Molecular imaging 19.3 | |
| Monetary incentive delay task M63, T61 | |
| Monetary reward M8, T87, W172 | |
| Monoamines M47 | |
| Monocytes W108 | |
| Monogamy T119 | |
| Mood 28, M70, T108 | |
| Mood and anxiety disorders 3, 38, T98, T107 | |
| Mood disorders 42.2, 44, M64, M83, M88, M89, T16 | |
| Morphometry M115 | |
| Motivation M48, M62, M180, W185, W194 | |
| Motor activity M67 | |
| Motor behavior T86 | |
| Motor evoked potentials T199 | |
| Mouse T81 | |
| Mouse behavior M127 | |
| Mouse genetics 32.3 | |
| mPFC M95, M100, T162 | |
| MRI 26.4, 42, 45.4, M66, T1, T186, W64 | |
| MRS W107 | |
| MRSI M128 | |
| Multimodal data 42.5 | |
| Multimodal neuroimaging T1, W121, W151 | |
| Multi-omics M168, W8, W56 | |
| Multiplex families 2.2 | |
| Multi-site MRI 31.3 | |
| Mu-opioid receptors 32.5, T28, T50, T171 | |
| Muscarinic acetylcholine receptor M88, W53 | |
| Muscarinic receptors T150 | |
| Myelination M30 | |
| Myosin M143 | |
| N,N-dimethyltryptamine (DMT) T58 | |
| N100 W119 | |
| N-acetylaspartate T122 | |
| N-acetylcysteine T145 | |
| NAD+ and NADH W98 | |
| Naltrexone T151 | |
| Nanoparticles 19.4 | |
| Natural dietary product W160 | |
| Natural language processing (NLP) W120 | |
| Natural setting T58 | |
| N-back T182 | |
| Negative emotionality T195 | |
| Negative reinforcement 34.4 | |
| Negative symptoms 21, M108, T136, W121, W129 | |
| Neonates 13.2 | |
| Network based statistic (NBS) T31 | |
| Neural circuitry 5 | |
| Neural circuit and animal behavior 10.4, 52.1, 52.3, M44, T51 | |
| Neural circuits 34.2, 41.2, M136 | |
| Neural decoding 19.5 | |
| Neural modelling W69 | |
| Neural network connectivity W69 | |
| Neural oscillations 24.1 | |
| Neural predictors T30, T88 | |
| Neurocircuitry W149 | |
| Neurocircuits 10, 19.2 | |
| Neurodevelopment 20.4, 38, 41.3, 45.4, 55, T59 | |
| Neurodevelopmental and behavioral deficits M11 | |
| Neurodevelopmental disorders 2, 26, W32, W108 | |
| Neuroeconomics W114 | |
| Neuroendocrine T71 | |
| Neuroepigenetic editing W7 | |
| Neuroepithelium 36 | |
| Neurofibromatosis type 1 M29 | |
| Neurogenetics 2.3 | |
| Neuroimaging 26, W34 | |
| Neuroimaging biomarkers 30 | |
| Neuroimmune T120 | |
| Neuroimmune interaction T180 | |
| Neuroimmune mechanisms M169, M185, T42, T45, T184, W167 | |
| Neuroinflammation 15.4, M99, T24, T145 | |
| Neuromelanin M8 | |
| Neuromelanin-sensitive MRI M13, T173, W153 | |
| Neurometabolism W136 | |
| Neuromodulation 19, 19.5 | |
| Neuromodulators 19.3 | |
| Neuronal ensemble 52, 52.1, 52.3, W143 | |
| Neuronal epigenome 25.3 | |
| Neuronal tracing T74, W190 | |
| Neuropathic pain 32, 32.3, M97, M148, T125 | |
| Neuropeptides M176, T118 | |
| Neuropharmacology 48.3, W88 | |
| Neurophysiology 46.3 | |
| Neuroplasticity 47, 47.2, 51.2, T121, W61, W107 | |
| Neuroplasticity hypothesis M93 | |
| Neuropsychiatric disorders [schizophrenia, Parkinson’s disease, major depressive disorder] 37.4, 46.3 | |
| Neuropsychology M78 | |
| Neuropsychopharmacology 19.4, 41.4 | |
| Neurosteroids T190 | |
| Neurostimulation 19 | |
| Neurotechnology 19.2 | |
| Neurotensin M43, T118 | |
| Next generation sequencing M148 | |
| N-glycosylation T36 | |
| Nicotine 36.2, M39, M153, M181, M183, W177 | |
| Nicotine addiction M151, W148 | |
| Nicotine demand M166 | |
| Nicotine dependence M170, W138 | |
| Nicotine vapor M170 | |
| Nicotine withdrawal W171 | |
| Nicotinic acetylcholine receptors W53 | |
| NMDA antagonists M130 | |
| NMDA glutamate receptors T40 | |
| NMDA Receptor M53, M118, M133, T199 | |
| NMDA receptor antagonist T106 | |
| NMDA receptors T146 | |
| NMDA receptors, MMN, ERP, auditory, training 6.4 | |
| NMDAR hypofunction M118 | |
| Non pharmacological interventions M79, T133 | |
| Non-coding RNA W147 | |
| Nonhuman primate model T83 | |
| Nonhuman primate models W168 | |
| Non-invasive brain stimulation T133 | |
| Non-invasive neuromodulation W170 | |
| Non-suicidal self-injurious behavior M65, T140 | |
| Non-suicidal self-injury (NSSI) T83 | |
| Noradrenaline M13, T156 | |
| Noradrenergic W144 | |
| Norepinephrine 14.2, T173, W22 | |
| Nosology 42.2 | |
| Novel antidepressant T65 | |
| Novel therapeutics 53, T185 | |
| Novelty response W22 | |
| Npas4 W145 | |
| NR2B receptor M89 | |
| NREM EEG gamma power M132 | |
| Nuclear factor kappa B T184 | |
| Nucleus accumbens 5.2, 9.2, 10, 10.2, 10.3, 34.3, 36.5, M3, M49, M144, M150, M162, M186, M188, M201, T41, T107, T119, T127, T165, T178, W14, W28, W55, W66, W145, W169, W183, W184, W185, W188, W189 | |
| Nucleus accumbens core W140 | |
| Nucleus accumbens shell 10.1, M146, T54 | |
| Nucleus reuniens W13 | |
| Number needed to treat W91 | |
| Obesity M37, T68, W46 | |
| Obsessive-compulsive disorder (OCD) 45.3, 46, 46.1, 46.2, M101, M102, M163, T31, T128, T129 | |
| Obsessive-compulsive spectrum disorders (OCDS) T127 | |
| Occipital pole M117 | |
| OCD T130 | |
| Olanzapine M111 | |
| Oleanolic acid acrylate T28 | |
| Oligodendrocytes 36 | |
| Omega-3 fatty acids W197 | |
| Operant behavior T181, T191 | |
| Opiate addiction W170 | |
| Opioid M99 | |
| Opioid abuse M172, M189, T192, W40 | |
| Opioid addiction 9.1, 34.3, 49.2, M144, M162, T38, T44, T50, T170, T171, T196, W140, W144, W159, W161, W188 | |
| Opioid dependence M148, T38 | |
| Opioid epidemic 50 | |
| Opioid epidemic—novel approaches W164 | |
| Opioid peptides M171 | |
| Opioid receptors T151 | |
| Opioid side-effects T45 | |
| Opioid use disorder T45, W153, W155, W158, W160, W164 | |
| Opioid withdrawal T171, W144 | |
| Opioids 7.4, 10, 32, 49.5, T48, W178 | |
| Opto-chemogenetics 52.2 | |
| Optogenetics 32.4, 41.2, M40, M100, M187, W20, W48 | |
| Orbitofrontal cortex (OFC) M59, T53, T130, T196, W141 | |
| Orexin 28.1, 28.3, T188 | |
| Orexin receptor antagonist 28, 28.2, W60 | |
| Orexin system W134 | |
| Organic cation transporters M147 | |
| Oscillation 6.4 | |
| Oscillations 48.5 | |
| Oxidative phosphorylation 54.4 | |
| Oxidative stress T67, W58 | |
| Oxycodone 9.1, 32.3, M142, T47, T187 | |
| Oxytocin W24, W26 | |
| Oxytocin and addiction 7.2 | |
| Oxytocin receptor 7.2 | |
| PACAP 32.5, M138 | |
| Pain 32.2, 32.5, 53, M175, T161, W1, W199 | |
| Pain analgesia M99, T45 | |
| Pain therapeutics W170 | |
| Paliperidone palmitate long-acting injection W110 | |
| Paranoia 6, 6.2 | |
| Paraventricular nucleus of the thalamus W134 | |
| Parenting distress M59, T167 | |
| Parkinsonism 45.2, 45.4 | |
| Parkinson’s disease 9.4, 46, M98 | |
| Partial agonist ligands T49 | |
| Parvalbumin 24.2, 48.2 | |
| Parvalbumin fast-spiking GABAergic interneurons 48.4, 48.5, M118 | |
| Patch foraging W153 | |
| Pathways T142 | |
| Patient outcomes W62, W86 | |
| Patient reported outcomes M137, T95 | |
| Pavlovian bias 39.3 | |
| Pavlovian conditioning M19, T9, T53, W184 | |
| Pediatric T128 | |
| Pediatric irritability W36 | |
| Pediatric PTSD 38.3 | |
| Pediatrics 38.4, W35 | |
| Perceived stress M173 | |
| Perceptual reasoning T77 | |
| Periaqueductal grey (PAG) 32.4 | |
| Perinatal T111 | |
| Perinatal stress 29, 29.4, M11 | |
| Perineuronal nets 36.4 | |
| Peripheral biomarker T90 | |
| Persistent avoidance T130 | |
| Personality T76 | |
| Personalized medicine 12.3, 46.4, 47.3 | |
| Positron emission tomography (PET) 15.2, 15.5, 43.3, M191, W157 | |
| Positron emission tomography (PET) Imaging 15.4, 43.5, T7, W32, W96, W165, W171, W173 | |
| PET imaging study M73, W40 | |
| PharmacoBOLD M105 | |
| Pharmacogenetics W73 | |
| Pharmacoepidemiology W73 | |
| Pharmacogenetics M69 | |
| Pharmacogenomic-guided treatment recommendations W73, W74 | |
| Pharmacogenomics T100 | |
| Pharmacologically-based nomenclature 18 | |
| Pharmacology 18 | |
| Pharmacotherapy 41.4, M148, T38 | |
| Phosphodiesterase-4 (PDE4) W104 | |
| Phosphoproteomics T39, W8 | |
| Phosphorylation W146 | |
| Physical activity W43 | |
| Physician-scientist 33 | |
| Physiologic biomarkers M91 | |
| Pimavanserin M129, T136, W59 | |
| Place cell W131 | |
| Placebo response M63, W76 | |
| Placebo-controlled trial W128 | |
| Plasma membrane monoamine transporter W176 | |
| Plasma psilocin W77 | |
| Pleiotropy analysis W123 | |
| Polydrug use M143 | |
| Polygenic risk scores W31, W32 | |
| Polygenic scores T35 | |
| Polysomnography T26, T158, W96 | |
| Positive emotion W84 | |
| Postmortem W125 | |
| Postmortem brain tissue 37.3, 54.4, T33, T179, W124 | |
| Postmortem human brain 37.4 | |
| Postpartum anxiety M80 | |
| Postpartum depression M80, T109, W80, W81, W91, W92 | |
| Prader Willi syndrome W24 | |
| Prairie vole T119 | |
| Pramipexole M56 | |
| Prebiotic treatment in schizophrenia W112 | |
| Precision medicine for mood and anxiety disorders 29.4 | |
| Precision medicine for mood disorders 29, 55 | |
| Precision psychiatry M56 | |
| Preclinical models and endpoints W1 | |
| Prediction 26.3 | |
| Predictive coding 6.2, T155 | |
| Predictive models 20.2 | |
| Predictor of treatment response W71 | |
| Prefrontal 24.2 | |
| Prefrontal circuit M119, T19 | |
| Prefrontal circuit maturation 24, M12 | |
| Prefrontal cortex 41.2, M34, M90, M135, T120, T182, W21, W30, W53, W63, W192 | |
| Pregnancy 51.2, T111, W27, W98 | |
| Prelimbic cortex M135, M160, T130 | |
| Premenstrual dysphoric disorder M73, M75 | |
| Prenatal drug exposure M161, W159 | |
| Prenatal stress 29.2 | |
| Prescription opioids M142, T38 | |
| Presymptomatic 26.4 | |
| Presynaptic mRNA T66 | |
| Probabilistic reversal learning 41.3, M126, M195, W200 | |
| Prodromal schizophrenia W119 | |
| Prodrome 12 | |
| Progesterone T4 | |
| Pro-inflammatory cytokines T123, W82 | |
| Proof of concept M25 | |
| Proopiomelanocortin neurons T194 | |
| Prophylactic M178 | |
| Propranolol M6 | |
| Protein aggregation T32 | |
| Proteomics 41.3, 54.5, W124, W146 | |
| Psilocybin 47.5, M41, M140, T46, T129, W77, W97 | |
| Psychedelic medicine 47, M140, T46 | |
| Psychedelics 16, 47.2, 47.3, 47.4, 47.5, M41, M85, T62, T108, T129, W49, W99 | |
| PsychENCODE 25.3 | |
| Psychiatric disease 25 | |
| Psychiatric education 33, W44 | |
| Psychiatric genetics 5.4, 20, T174 | |
| Psychological effects T58 | |
| Psychological pain T99 | |
| Psychomotor speed W174 | |
| Psychomotor symptoms 45.1 | |
| Psychoneuroimmunology T180 | |
| Psychopharmacology treatment guidelines W90 | |
| Psychophysiology 14.4, W17 | |
| Psychosis 6.2, 30.4, 42.2, 54, M113, M115, M131, T132, T146, T152, W35, W116, W122, W137, W198 | |
| Psychosis continuum 6.2 | |
| Psychosis spectrum M122 | |
| Psychosis spectrum disorders 47.3 | |
| Psychostimulants W25 | |
| Psychotherapy T5, T167 | |
| Psychotic depression W128 | |
| Psychotic disorders 42 | |
| Psychotic-like experiences M98 | |
| Psychotropic medications 18, T139, W42 | |
| Post traumatic stress disorder (PTSD) 2, 2.1, 14.3, 14.4, 14.5, 23.5, 37.3, 51, 51.1, M2, M3, M10, M13, M14, M17, T3, T4, T5, T7, T72, T167, W9, W10, W12, W13, W14, W16, W63, W134 | |
| Pubertal stress M85, W89 | |
| Puberty T71 | |
| Public health T168 | |
| Punishment T170 | |
| Pupillometry 14 | |
| Pyramidal neuron 54.4 | |
| qFISH M38 | |
| QIDS-SR16 W68 | |
| Quality of life T183 | |
| Quantitative EEG M140 | |
| Quantitative electroencephalography (qEEG) M182 | |
| Quetiapine M98, T24 | |
| R-(-)-ketamine T115 | |
| Racial differences W82 | |
| Racism 51, 51.1, T10 | |
| Raclopride M63, M96 | |
| Randomized clinical trial T5, T136 | |
| Randomized controlled trial 7.5 | |
| Rapid antidepressant M53, M84 | |
| Rapid mood screener W87 | |
| Rapid-acting antidepressant T115 | |
| Ras/MAPK pathway T13 | |
| RASopathies M29 | |
| Rats W20 | |
| RCT M69 | |
| Real-time fMRI W64 | |
| Real-time fMRI neurofeedback M25, W84, W85, W194 | |
| Receptor binding T28 | |
| Receptor internalization, trafficking W166 | |
| Recidivism M36 | |
| Recordings W20 | |
| Recovery 22 | |
| Redox dysregulation 54.3 | |
| Reelin M87 | |
| Registry T111 | |
| Regulatory policy 16 | |
| Regulatory variation 20.4 | |
| Reinforcement M188 | |
| Reinforcement learning 44, M16, W192 | |
| Reinforcement learning modelling M195 | |
| Reinforcement-based decision-making T191 | |
| Reinstatement M166, M177, T170 | |
| Relapse T29 | |
| REM sleep 49.4, M138, M159, T160 | |
| Remission 38.3 | |
| Remote memory W30 | |
| Repetitive behavior W24 | |
| Repetitive transcranial magnetic stimulation (rTMS) M21, M35, M91, T90, T199, W63, W86 | |
| Reproduction M48 | |
| Research domain criteria (RDoC) 55, T59 | |
| Residency training 33 | |
| Residential treatment 39.4 | |
| Resilience 34.4, M197 | |
| Resiliency M172 | |
| Respiration T112 | |
| Resting state 38.5, W116 | |
| Resting state functional connectivity 12.2, 13.4, M123, M130, T13, T56, T59, W25, W106, W138 | |
| Resting state intrinsic connectivity T55 | |
| Resting-state fMRI 6.5, 45.2, M65, M191, T5, T31, T128, W39, W77, W120, W127 | |
| Retina 49.3 | |
| Retrotransposon 25.4 | |
| Reversal learning T80 | |
| Reward 27, 27.1, 49, M63, M153, M158, T76, W20, W28, W156 | |
| Reward and aversion M145 | |
| Reward anticipation T177 | |
| Reward circuitry 34, 34.3, 46, M162, W143 | |
| Reward functioning M61 | |
| Reward learning M161, M190 | |
| Reward memory W97 | |
| Reward neural circuitry 38.5, W67 | |
| Reward sensitivity W52 | |
| Reward-based decision-making 39.3, M62, T191, W153 | |
| Reward-seeking behavior M84, W115, W139 | |
| Rhesus M18 | |
| Risk and resilience 38.5, 39.1, M9, M11, W121 | |
| Risk calculator 12.1, 12.3 | |
| Risk taking behaviors W141 | |
| RNA splicing W147 | |
| RNAseq 10, 10.2, 49.4, T16, T18, T41, T107, T142, T156, W8, W56, W79 | |
| Rodent models 6.3, M62, T47, W11 | |
| Rosuvastatin T94 | |
| Rumination T56 | |
| Safety 39.2 | |
| Salience 27.1 | |
| Salience network 13.4, T31 | |
| Salvinorin A T62 | |
| Samidorphan M111, T151 | |
| Schizoaffective disorder W112 | |
| Schizophrenia (SCZ) 2.2, 6.3, 25.2, 37, 42.3, 43, 43.4, 45.1, 45.2, 45.3, 45.4, 48.2, 54.3, 54.4, M64, M106, M107, M108, M111, M114, M117, M118, M120, M122, M124, M125, M126, M128, M134, M136, M200, T25, T32, T33, T34, T36, T104, T134, T135, T136, T138, T139, T141, T143, T145, T146, T148, T150, T153, T154, T160, W110, W112, W114, W118, W121, W122, W123, W124, W125, W126, W129, W133, W134, W136, W138 | |
| Schizophrenia and bipolar disorders 37.5, T140 | |
| Schizophrenia negative symptoms 42.4 | |
| Schizophrenia novel treatment 43.2, M71, T133, T137, T142, W130 | |
| Schizophrenia prodrome 8 | |
| Schizophrenia spectrum disorders 30, T197 | |
| Schizophrenia subtypes 43.5, M116, T32 | |
| Schizophrenia, antipsychotics 43.3, M110, T35, T37 | |
| Schizophrenia, synaptic aberrations 6.5, 48, M200 | |
| Schizophrenia; functional capacity; technology W132 | |
| Schizophrenia; technology 42.4 | |
| Schizophrenia-like behavior W135 | |
| Scopolamine M88 | |
| Screening W87 | |
| Seahorse T112 | |
| Self-administration 41.4, M177, T50, W51, W148, W177, W187 | |
| Self-regulation W194 | |
| Seltorexant W60 | |
| Sensorimotor M23, T86 | |
| Septum 36.2 | |
| Sequencing M120 | |
| Serious mental illness 4 | |
| Serotonin 3.2, M180, T91, T189, W6, W52, W89 | |
| Serotonin 1b receptor W52 | |
| Serotonin 5-HT2A receptor 47.4, M85, W200 | |
| Serotonin 5-HT2C receptor M192 | |
| Serotonin transporter M73 | |
| Serotonin transporter genotype T83 | |
| SERT W6 | |
| Serum levels M92 | |
| Set shifting 24.2 | |
| Severe major depressive disorder W62 | |
| Sex 23.3 | |
| Sex chromosomes W179 | |
| Sex differences 3, 3.1, 3.4, 23, 24.4, 27, 27.1, 27.2, 27.3, 34, 34.5, 37.2, 37.4, 37.5, M16, M30, M32, M44, M94, M147, M189, T12, T67, T68, T71, T79, T96, T123, T164, T178, T181, T187, T193, W7, W39, W55, W79, W89, W142, W146, W157, W173, W178, W179, W188 | |
| Sex hormones 2.1, T67, W142 | |
| Sexual dimorphism 34.2, 36.3 | |
| SGE-516 T190 | |
| Shank3 T40 | |
| Shati/Nat8l M95 | |
| Short tandem repeat M120 | |
| Side effects W42 | |
| Sigma-1 receptor T161 | |
| Signal detection T169 | |
| Sign-tracking M151 | |
| Simulated data 42.5 | |
| Simulated driving T168 | |
| Simultaneous PET-MR M96 | |
| Single-cell analysis 51.4 | |
| Single-cell RNA sequencing 20.5, 36, W109, W148 | |
| Skin conductance response T44, T57, W16 | |
| SLC39A8 T36 | |
| Sleep 49, M67, M70, M138, M189, T99, T116, T152, T159 | |
| Sleep architecture M132, M140 | |
| Sleep deprivation T26 | |
| Sleep disturbance 49.2, M27, M132, T97 | |
| Slow wave sleep M159, T26 | |
| Smartphone W48 | |
| Smartphone apps W164 | |
| Smoking M153, W154 | |
| Smoking cessation W177 | |
| SMS text messaging M109 | |
| SNRI M72 | |
| Sociability W41 | |
| Social anxiety M8, T71 | |
| Social attention T169 | |
| Social behavior 24, 24.3, 24.4, 40, M32, M34, M100, M141, T84, T123 | |
| Social brain M153 | |
| Social cognition T197 | |
| Social communication T78 | |
| Social defeat 40 | |
| Social defeat stress 10.2, M52, M76, T192 | |
| Social dominance T91 | |
| Social factors and functioning T180 | |
| Social functioning 31.1 | |
| Social interaction M28, M161 | |
| Social isolation 24.3, M34, W43, W115 | |
| Social media monitoring W160 | |
| Social motivation M51, M96 | |
| Social processing T169 | |
| Social recognition memory M20, M32 | |
| Social rejection M8 | |
| Social responsiveness M22 | |
| Social withdrawal T107 | |
| Socio-economic status M26, T10 | |
| Somatic mosaicisms 25.4 | |
| Somatostatin 48.2 | |
| Speed of processing W118 | |
| Sphingosine 1-phosphate receptor T125 | |
| Sphingosine-1-phosphate W105 | |
| Spironolactone M167 | |
| Src family kinases M87 | |
| Selective serotonin reuptake inhibitors (SSRIs) M11, M72, T70, W93 | |
| SSRT M154 | |
| Statistical methods W86 | |
| Stem cells T142, W108 | |
| Stimulants W37, W173 | |
| Strategy switching M155 | |
| Stress 23.3, 32.3, 52.1, M70, M86, T120, W19, W27 | |
| Stress and anxiety behavior 14.5, M176, W197 | |
| Stress and anxiety disorders M11, M116 | |
| Stress and depression 3.1, T60 | |
| Stress and trauma 23, 23.2, 51.3, M17, M24, T82, W21 | |
| Stress coping M197, W13 | |
| Stress models 24.4, 34.5, 36.3, W180 | |
| Stress reactivity M131, M169, T60, W165 | |
| Stress resilience and susceptibility M12, M194, T30 | |
| Stress-induced dopamine release T171 | |
| Striatal dopamine signaling T63 | |
| Striatum 6.3, 9.3, 10.4, M8, M102, T9, T158, W125 | |
| Structural and functional connectivity 13.3 | |
| Structural MRI 5.4, 45.2, M12, T15, T154, W120 | |
| Structural neuroimaging 12.4 | |
| Structure of psychopathology 55 | |
| Subcallosal cingulate W83 | |
| Subcortical shape analysis M26 | |
| Subcortical-cortical motor loops 45.1 | |
| Subgenual anterior cingulate T16 | |
| Substance abuse M123 | |
| Substance abuse disorders 22, 39.4, T167, T174 | |
| Substance use disorders 50, M3, T48, T169, T178, W186, W199 | |
| Substantia nigra T50 | |
| SUD-like phenotypes W175 | |
| Suicidal behavior M65, T140 | |
| Suicidal ideation M65, T93, T95, T99, T140 | |
| Suicidality 5, 5.5, M60 | |
| Suicide T99, T116, W84 | |
| Suicide prediction 5.5 | |
| Sulforaphane M22, T137 | |
| Susceptibility 34.4 | |
| SV2A protein 43.3 | |
| Symptom trajectory M9 | |
| Synapse T120 | |
| Synapse pruning 43.4 | |
| Synapses 43.2 | |
| Synaptic aberrations 32.3, 48 | |
| Synaptic density 43 | |
| Synaptic function W99 | |
| Synaptic plasticity 10.3, 32.3, 48.3, 52.1, M3, M15, T199 | |
| Synchrony T30 | |
| Synthetic psychoactive cathinones W175 | |
| Systematic review T197 | |
| Systemic inflammation W198 | |
| Systems biology 29.3 | |
| Systems neuroscience 14, W148 | |
| TAAR1 M108, T149, W6 | |
| Target engagement W26 | |
| Task-based functional connectivity T78, W11 | |
| TBI T79, W106 | |
| TDCS W10 | |
| Temperament T84 | |
| Temporal discrimination W131 | |
| Testosterone T65, T71 | |
| Tetrapartite synapse M3, M144 | |
| Thalamus 24.3, M130 | |
| THC M174 | |
| Th-Cre M187 | |
| Theta 6.4 | |
| Theta burst transcranial magnetic stimulation M10 | |
| Theta-burst stimulation M14 | |
| Time cell W131 | |
| Time-frequency 6.4 | |
| Timing M188 | |
| TMS T101 | |
| TMS-EEG T153, W107 | |
| Tobacco smoking W171 | |
| Tolerance W174 | |
| Top-down W196 | |
| Top-down control M119 | |
| Touchscreen M196, T156, W115 | |
| Training 1 | |
| Transcriptome 20.2, T141 | |
| Transcriptomics 14.5, 37.3, T66, W8, W109 | |
| Transdiagnostic 5, M199, M200, W191 | |
| Transforming growth factor beta-1 T115 | |
| Transgenerational M15 | |
| Transgenerational epigenetic effects M11 | |
| Transgenic mice M133, W4, W104, W162 | |
| Transgenic models M194 | |
| Translating innovation 53 | |
| Translational approaches to drug development 7 | |
| Translational neuroscience 5, 9.2, 19.2, 22, 28.3, W181 | |
| Translational pharmacology M167 | |
| Translational research T6, T108 | |
| Translatomics W8 | |
| Trauma W17 | |
| Trauma exposure T1, T69 | |
| Traumatic brain injury 15.2 | |
| Treatment M79, W160 | |
| Treatment adherence M109, W155 | |
| Treatment mechanisms 7 | |
| Treatment outcome prediction T88, W155 | |
| Treatment prediction W70 | |
| Treatment resistant depression 3.2, M68, T18, T90, T116, W85 | |
| Treatment response 42.5 | |
| Treatment-refractory depression W95 | |
| Treatment-resistant schizophrenia M112 | |
| Treatment-response M55 | |
| TRIP8b M50 | |
| TrkB M20, W169 | |
| Tryptophan catabolites (TRYCAT) M92, T160 | |
| TSPO 43, 43.5 | |
| TSPO and [11C]PBR-28 PET 43.3, M165, T7, T45 | |
| Two-photon calcium imaging T126, T155 | |
| Two-photon imaging 14.2 | |
| Type 1 corticotropin releasing factor receptor M1 | |
| Type-2 diabetes 30.4 | |
| Ultra high-risk youth 8 | |
| Ultrasonic vocalization W11 | |
| Uncertainty W189 | |
| Underrepresented 35 | |
| V1aduct W101 | |
| Vagus nerve M77 | |
| Valence 27.1, T118 | |
| Validation 40, W1 | |
| VANILLA W101 | |
| Vaping M179 | |
| Vapor W135 | |
| Vascular endothelial growth factor T90 | |
| Ventral attention network T6, T31 | |
| Ventral capsule/ventral striatum 9.3 | |
| Ventral hippocampus 39.2, M136, T14, T74, W66 | |
| Ventral pallidum 9.1, 52.2, M145, T166 | |
| Ventral tegmental area (VTA) 27.2, 32.4, M52, M186, T52 | |
| Ventromedial prefrontal cortex T73, W84 | |
| Verbal learning T137 | |
| Veterans W63, W106 | |
| Violence T139 | |
| Visual attention M119 | |
| Visual cortex 14.5, M119, T126 | |
| Visual processing M103 | |
| Visuospatial ability T121 | |
| Visuospatial working memory T137, T138 | |
| vmPFC W10 | |
| Voltage-gated calcium channel M193 | |
| Voxel-based morphometry (VBM) M163 | |
| Vulnerability M172, W66 | |
| Vulnerability traits 23.4 | |
| White matter fractional anisotropy M46 | |
| White matter integrity W9 | |
| Whole-brain rodent imaging 7.4, W3 | |
| Whole-cell patch clamp recording W184 | |
| Whole-genome M120 | |
| Wistar Kyoto rat M140 | |
| Withdrawal M39, M148, M170, M189, T38 | |
| Women’s health T111 | |
| Women’s mental health W93 | |
| Working memory 48.2, M157, T20, T69, T182 | |
| Worry T56 | |
| Xanomeline T150 | |
| Youth M4, M199 | |
| Zebrafish M31, W69 | |
| Zuranolone T109, W91 | |
| α5-GABAA receptor negative allosteric modulator M84 |
. 2020 Dec 6;45(Suppl 1):415–429. doi: 10.1038/s41386-020-00894-3